#United States #New York #Class Action #Gross Law Firm #Cytokinetics

Gross Law Firm Initiates Class Action Lawsuit on Behalf of Cytokinetics Shareholders

The Gross Law Firm has officially announced the initiation of a securities class action on behalf of shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). This announcement comes as a critical warning for investors who purchased shares of CYTK during the specified class period, which spans from December 27, 2023, to May 6, 2025.

This class action has been triggered by allegations that the company and its executives made materially false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and the subsequent FDA approval process for their drug aficamten. According to the lawsuit, Cytokinetics projected that it would receive FDA approval for aficamten in the latter half of 2025, basing this claim on a PDUFA date of September 26, 2025. However, they failed to disclose significant risks related to the submission of a vital Risk Evaluation and Mitigation Strategy (REMS), a potential oversight that could jeopardize the regulatory timeline.

During a May 6, 2025 earnings call, the truth began to unravel. It became apparent that although the Company had engaged in several pre-NDA meetings with the FDA concerning safety monitoring and risk mitigation strategies, their decision to submit the NDA without a REMS seemed reckless. This omission misled investors into believing that the approval process was well on track and more predictable than it actually was. Following the revelation of these misleading details, the stock's value, which had been artificially inflated as a result of these statements, suffered a significant downturn, leading class members to experience substantial financial losses.

Important Deadlines for Shareholders

Shareholders of Cytokinetics are urged to act swiftly, as the deadline for registering in this class action is set for November 17, 2025. It is crucial for those who acquired Cytokinetics shares during the outlined period to register their details with the Gross Law Firm, even if they do not wish to serve as lead plaintiffs.

By registering, shareholders will gain access to an exclusive portfolio monitoring software that will keep them informed throughout the legal proceedings. This is an effective way for investors to stay updated on developments related to their case, ensuring that they do not miss important deadlines or updates.

Why Choose the Gross Law Firm?

The Gross Law Firm has built its reputation as a nationally recognized class action law firm, dedicated to the protection of investors’ rights. Their mission is clear: to hold companies accountable for deceptive practices and to ensure that responsible business operations are upheld. They focus not only on recovering losses for investors but also on advocating for transparency and ethical standards in corporate governance.

Their extensive experience in class action lawsuits empowers shareholders who have been affected by misleading statements and practices of companies like Cytokinetics. The firm is committed to seeking justice for all clients involved in the lawsuit, with no costs or obligations placed on shareholders who participate in this legal venture.

Conclusion

Investors affected by Cytokinetics’ misleading statements regarding the aficamten approval process have an opportunity to join the class action initiated by the Gross Law Firm. With the deadline approaching, it is essential for shareholders to act promptly and secure their rights. The Gross Law Firm stands ready to assist in this journey toward justice and accountability for their clients.

For further details, shareholders can contact The Gross Law Firm directly:
Address: 15 West 38th Street, 12th floor, New York, NY, 10018
Phone: (646) 453-8903
Email: [email protected]